On the other hand, studies with omalizumab (anti‐IgE) showed that treatment ameliorated clinical symptoms of CRSwNP, reduced nasal polyp size, but had only limited effects on blood eosinophil levels [17]. The gene discussed is IGHE; the disease is nasal cavity polyp.